Animal study · mice
Survodutide: more weight loss than semaglutide in mice
Checked against the paper Animal studyPublished by PepVault
The takeaway
This early lab paper shows that survodutide acts on both the glucagon and GLP-1 receptors and beat semaglutide for weight loss in mice; whether that holds in people is a question for human trials.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2022
- Journal
- Mol Metab
What they tested
The team set out to describe how survodutide (BI 456906) acts at two receptors, the glucagon receptor and the GLP-1 receptor, and whether it lowers body weight.
How the study was done
A preclinical study that used lab cell tests and mice given acute or repeated short-term (subchronic) doses, compared against semaglutide. It also used mice lacking the GLP-1 receptor (knockout mice), transgenic reporter mice, and an ex vivo bioactivity assay.

Model. Individual results vary.
What they found
In mice, pharmacological doses of survodutide cut body weight more than maximally effective doses of semaglutide, a GLP-1 receptor drug. The extra effect came from more energy burned plus less food eaten. Action at the GLP-1 receptor showed up in glucose tolerance, food intake and gastric emptying (how fast the stomach empties) tests. Action at the glucagon receptor showed up in liver nicotinamide N-methyltransferase mRNA levels and blood markers, including amino acids and fibroblast growth factor-21.
What it doesn’t show
This is mouse and cell work, so it is not a result in people. The mouse dosing was short-term, and the study did not test survodutide in humans.
The paper
Zimmermann et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022.
The compound
More studies on Survodutide
- Survodutide: up to 13.0% weight loss at 76 weeks in SYNCHRONIZE-1Randomized trial · people · 2026
- Survodutide: 12.2% weight loss and less liver fat at 48 weeksRandomized trial · people · 2026
- Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trialRandomized trial · people · 2024
- Every study on Survodutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.